Gaussian-process-assisted engineering of a ketoreductase for an ipatasertib precursor
A six-round engineering campaign combined mutational scans, structure-guided libraries and Gaussian-process models. The model-aided library yielded M3, reported with 22-fold higher apparent activity than wild type in the UV assay. Three subsequent conventional mutagenesis rounds produced M6, a 10-substitution descendant with 64-fold higher apparent kcat, but also about 12-fold higher apparent KM; do not attribute M6 as a direct model output or treat kcat as production yield. The authors report a 100 g/L laboratory process test with ≥98% conversion and 99.7% diastereomeric excess after 30 hours. These are process-relevant laboratory results, not a commercial production run or drug efficacy.
Technology: Gaussian-process regression
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: M3 and later M6 were tested for activity; article reports preparative reactions at 100 g/L substrate and conversion/stereoselectivity under specified laboratory conditions.
- Still unknown: M6 follows conventional site-mutagenesis rounds after the AI-informed step; apparent kcat differs from process yield and KM changed; no commercial production/clinical efficacy claim.
- AI role: Gaussian-process predictions informed smaller follow-up variant libraries within a broader workflow that also used mutational scanning, rational design and conventional evolution.
Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC10902378/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review date: 16 Nov 2026. Review scope: Primary PMC full article, methods/results, publication history, affiliations and chronology of model and conventional rounds..
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.